Farshad Sheybaee Moghaddam

Research fellow of Urologic Oncology, Norris Cancer Center @USC_Urology | Proud dad of furry felines 🐈🐈

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

Beyond thrilled to match at my dream program @uwurology ! Forever grateful for the unparalleled mentorship of @Hoomandjaladat & @siadaneshmand , and who made this happen… @alirezaghoreifi
Endless gratitude to my incredible wife
Thanks to my family @USC_Urology !
#uromatch2025

[UW Urology @uwurology]

Happy Match Day!

We’re excited to welcome Karissa Yamaguchi, Shannon Richardson, Farshad Sheybaee Moghaddam, and Gabriella Sarriera Valentin to the Department of Urology at @uwmedicine!

#UWUrology

[Journal of Clinical Oncology @JCO_ASCO]

TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. Co-authored by @siadaneshmand.

Read the full article. https://t.co/v3BAbHrVRP
#blcsm

[Alireza Ghoreifi, MD @alirezaghoreifi]

Great job by my colleagues @FarshadSheybaee @RKSayyid and the ROBUUST collaborative group!

[Masatomo Kaneko @KanekoMasatomo]

Thrilled to see the phase 3 RCT of vesicopexy on urinary continence and QOL following RARP, led by @Hoomandjaladat, presented at the Clinical Trials in Progress session! A truly impactful study on a critical topic. #AUA25 @alirezaghoreifi @FarshadSheybaee @USC_Urology

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

@Hoomandjaladat presents Vesicopexy Trial experience
@USC_Urology #AUA2025

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

Don't miss @Hoomandjaladat at #AUA2025 as he presents our experience from the Vesicopexy trial.
Join us for insights during the 'Clinical Trials in Progress: Prostate & Kidney Cancer' session.
@USC_Urology @AmerUrological

[Alireza Ghoreifi, MD @alirezaghoreifi]

Happening now: An all 🌟 panel of experts is sharing insights on precision medicine and the evolving landscape of bladder cancer care at #AUA2025
@siadaneshmand @LauraBukavinaMD @spsutkaMD @MattGalsky @PeerView @BladderCancerUS

[BackTable Urology @_backtableUro]

Next up, check out #URO92 with @siadaneshmand to review the modern management of stage 2 seminoma @TestesCancer @TCSociety #testicularcancerawarenessmonth

https://t.co/a8AvG2tl0Y

[Judith C Hagedorn @jc_hagedorn]

@uwurology @TovaLWeiss #AUA2025 Dr. Tova Weiss presenting her device to prevent catheter trauma at Innovation Nexus. Congratulations

[SWIU @SWIUorg]

This year's @SWIUorg outstanding resident award will be presented to Dr @chloepetersMD at the SWIU-AUA breakfast! Congratulations!🌟

@uwurology

[Judith C Hagedorn @jc_hagedorn]

@SorensenMathew @uwurology
Congrats on the well deserved award for substantial contributions to the SAU.
@UroAcademic

[Alireza Ghoreifi, MD @alirezaghoreifi]

Just published in @icurology
➡️Post-hoc analysis of PUBMIC trial >> learning curve effect in surgical trials
📉Temporal improvement in 90d stoma complications
📉Downtrending of clinical and surgery for PSH
@FarshadSheybaee @Hoomandjaladat
🔗 https://t.co/g253XBpMgf

[UroToday.com @urotoday]

The effect of enhanced recovery after surgery on oncologic outcome following radical cystectomy for urothelial bladder carcinoma. #AuthorCommentary

Does ERAS impact oncologic outcomes after radical cystectomy?

A study of 2111 patients found ERAS reduces hospital stay & improves short-term recovery but does not independently affect recurrence-free or overall survival.

🔍 Key insights for bladder cancer surgery > https://t.co/Hd1f0ZQA8X @Runzhuo_Ma @Hoomandjaladat #SurgicalOncology

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

Don't miss @Hoomandjaladat at #AUA2025 as he presents our experience from the Vesicopexy trial.
Join us for insights during the 'Clinical Trials in Progress: Prostate & Kidney Cancer' session.
@USC_Urology @AmerUrological

[Mazyar (Menachem) Zahir, M.D. @MazyarZahir]

Join the legendary @siadaneshmand at #AUA2025 for an expert take on advancing bladder cancer care.
Proud to be part of his incredible team
@LeileiXiaUro
@chirag_doshi1
@FarshadSheybaee @alirezaghoreifi
@USC_Urology
@AmerUrological

[Grand Rounds Urology @GRUrology]

.@siadaneshmand, @USC_Urology, discusses recent updates in bladder cancer guidelines, focusing on the 2024 NCCN and AUA recommendations.

#Urology #AUA2024 #Bladder

[Bladder Cancer Advocacy Network @BladderCancerUS]

Gain insights on the latest data on advanced drug delivery techniques, targeted agents, and immunotherapy for #bladdercancer with Drs. @siadaneshmand, @LauraBukavinaMD, @MattGalsky. 4/28 at 7:30 AM PDT. Hosted by @PeerView at #AUA25. https://t.co/odrzs2xA5b

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

@nader_shayegh @danaebyer Congratulations! That's awesome 👍 🎉👏

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

Delighted to share our new paper on UTUC

📊 883 pts (15% NAC) from ROBUUST 2.0
🚨 ypN+: worse 5yr OS vs. pN+ (20% vs. 31%)
📉 All ypN+ had mets at 1yr, 13% pN+ mets-free
🔄 Recurrence patterns vary by nodal/NAC
🔗https://t.co/VmFBnReezD
@Hoomandjaladat @USC_Urology @UrolOncol

[Sia Daneshmand, M.D. @siadaneshmand]

It was an honor presenting the @UroOnc #SUO lecture @Uroweb #EAU25 on updates in ERAS. New guidelines coming in 2025! @saumyg @ErasSociety. Thanks you @JimCatto @KariTikkinen @bkonety

[Farshad Sheybaee Moghaddam @FarshadSheybaee]

@Naderian_mr @BCM_InternalMed Congratulations! Well deserved 🎉🍾 👏🏻

[UroToday.com @urotoday]

Safety and tolerability of TAR-200 monotherapy in patients with BCG-unresponsive high-risk #NMIBC in #SUNRISE-1. @siadaneshmand @KECKSchool_USC joins @zklaassen_md @GACancerCenter to discuss on UroToday. The Phase IIb study demonstrates an impressive 83.5% complete response rate with the device, which remains in place for three weeks at a time. #WatchNow on UroToday > https://t.co/UbHlZUMhNh